Puma Biotechnology Q3 2023 Earnings Report

Puma Biotechnology EPS Results

• Actual EPS: $0.12
• Consensus EPS: $0.08
• Beat/Miss: Beat by +$0.04
• One Year Ago EPS: N/A

Puma Biotechnology Revenue Results

• Actual Revenue: $56.10 million
• Expected Revenue: $57.30 million
• Beat/Miss: Missed by -$1.20 million
• YoY Revenue Growth: N/A

Puma Biotechnology Announcement Details

• Quarter: Q3 2023
• Date: 11/2/2023
• Time: N/A

Puma Biotechnology (NASDAQ:PBYI), a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.